Additionally, many of the biomarkers that exhibited a significant AD-slowing drug effect (NG, SNAP25, YKL40, sMRI and [18F]-FDG PET) correlated highly with cognitive function at baseline in the trial cohort (Extended Data Fig. 1) and were linked to longitudinal changes in cognition through larger studies with a longer duration76–78. Here, CHI3L1 is linked to Alzheimer disease.